Pharmaceutical firm Eisai Co. said April 25 it will establish a new production plant at the Suzhou Industrial Park in Suzhou, Jiangsu province, China, to supply injection products.
Eisai forecasts sustained growth in the Chinese pharmaceutical market, citing a sharp increase in demand for its Methycobal injection, one of Eisai’s major products in China, as a drug for peripheral neuropathies.
Injection products produced at Suzhou plant will also be considered for supply to emerging economies in Asia and Central and South America, with the goal of having the Suzhou plant function as a global supply base.
Construction of the Suzhou plant is scheduled to be completed during the first half of fiscal 2014.
- « Prev
- Next »